Scleredema. A multicentre study of characteristics, comorbidities, course and therapy in 44 patients

F. Rongioletti, F. Kaiser, E. Cinotti, D. Metze, M. Battistella, P. G. Calzavara-Pinton, K. Damevska, G. Girolomoni, J. André, J. L. Perrot, W. Kempf, B. Cavelier-Balloy

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Background The prognostic and therapeutic features of scleredema are poorly documented. Objectives To describe the characteristics of patients with scleredema regarding demographics, clinical characteristics, comorbidities, therapeutic interventions and course. Methods We conducted a retrospective multicentre study. Results We identified 44 patients (26 men).The mean age at diagnosis was 53.8 years. The most common associated disorders were endocrine/metabolic diseases including 30 patients suffering from diabetes, mostly type 2 diabetes. Monoclonal gammopathies were confirmed in five cases. A preceding respiratory tract infection was not a feature. Treatments with different combination or sequential modalities were used with variable results. Phototherapy (UVA1 or PUVA) was the treatment associated with higher, although partial response. Systemic corticosteroids and immunosuppressive drugs were reserved to patients with severe disease in whom phototherapy had failed or for patients with multiple myeloma. Forty-one patients were followed up (mean period: 32.2 months).Thirty-nine patients are alive, 30 with and 9 without skin disease. Two patients died of cardiovascular complications due to myeloma and severe diabetes. Conclusions Scleredema is a chronic debilitating disease associated with diabetes and metabolic syndrome, unresponsive to various treatments but not necessarily a life-threatening condition. Although there is no definitive treatment, phototherapy should be attempted first. Treatment of primary disease including strict glycaemic control combined with physical therapy should be also employed.

Original languageEnglish
Pages (from-to)2399-2404
Number of pages6
JournalJournal of the European Academy of Dermatology and Venereology
Volume29
Issue number12
DOIs
Publication statusPublished - Dec 1 2015

Fingerprint

Scleredema Adultorum
Multicenter Studies
Comorbidity
Phototherapy
Therapeutics
Endocrine System Diseases
Paraproteinemias
Metabolic Diseases
Immunosuppressive Agents
Multiple Myeloma
Skin Diseases
Respiratory Tract Infections
Type 2 Diabetes Mellitus
Adrenal Cortex Hormones
Chronic Disease
Retrospective Studies
Demography

ASJC Scopus subject areas

  • Dermatology
  • Infectious Diseases

Cite this

Rongioletti, F., Kaiser, F., Cinotti, E., Metze, D., Battistella, M., Calzavara-Pinton, P. G., ... Cavelier-Balloy, B. (2015). Scleredema. A multicentre study of characteristics, comorbidities, course and therapy in 44 patients. Journal of the European Academy of Dermatology and Venereology, 29(12), 2399-2404. https://doi.org/10.1111/jdv.13272

Scleredema. A multicentre study of characteristics, comorbidities, course and therapy in 44 patients. / Rongioletti, F.; Kaiser, F.; Cinotti, E.; Metze, D.; Battistella, M.; Calzavara-Pinton, P. G.; Damevska, K.; Girolomoni, G.; André, J.; Perrot, J. L.; Kempf, W.; Cavelier-Balloy, B.

In: Journal of the European Academy of Dermatology and Venereology, Vol. 29, No. 12, 01.12.2015, p. 2399-2404.

Research output: Contribution to journalArticle

Rongioletti, F, Kaiser, F, Cinotti, E, Metze, D, Battistella, M, Calzavara-Pinton, PG, Damevska, K, Girolomoni, G, André, J, Perrot, JL, Kempf, W & Cavelier-Balloy, B 2015, 'Scleredema. A multicentre study of characteristics, comorbidities, course and therapy in 44 patients', Journal of the European Academy of Dermatology and Venereology, vol. 29, no. 12, pp. 2399-2404. https://doi.org/10.1111/jdv.13272
Rongioletti, F. ; Kaiser, F. ; Cinotti, E. ; Metze, D. ; Battistella, M. ; Calzavara-Pinton, P. G. ; Damevska, K. ; Girolomoni, G. ; André, J. ; Perrot, J. L. ; Kempf, W. ; Cavelier-Balloy, B. / Scleredema. A multicentre study of characteristics, comorbidities, course and therapy in 44 patients. In: Journal of the European Academy of Dermatology and Venereology. 2015 ; Vol. 29, No. 12. pp. 2399-2404.
@article{67663a5133b64ef9843705ec8dfc9308,
title = "Scleredema. A multicentre study of characteristics, comorbidities, course and therapy in 44 patients",
abstract = "Background The prognostic and therapeutic features of scleredema are poorly documented. Objectives To describe the characteristics of patients with scleredema regarding demographics, clinical characteristics, comorbidities, therapeutic interventions and course. Methods We conducted a retrospective multicentre study. Results We identified 44 patients (26 men).The mean age at diagnosis was 53.8 years. The most common associated disorders were endocrine/metabolic diseases including 30 patients suffering from diabetes, mostly type 2 diabetes. Monoclonal gammopathies were confirmed in five cases. A preceding respiratory tract infection was not a feature. Treatments with different combination or sequential modalities were used with variable results. Phototherapy (UVA1 or PUVA) was the treatment associated with higher, although partial response. Systemic corticosteroids and immunosuppressive drugs were reserved to patients with severe disease in whom phototherapy had failed or for patients with multiple myeloma. Forty-one patients were followed up (mean period: 32.2 months).Thirty-nine patients are alive, 30 with and 9 without skin disease. Two patients died of cardiovascular complications due to myeloma and severe diabetes. Conclusions Scleredema is a chronic debilitating disease associated with diabetes and metabolic syndrome, unresponsive to various treatments but not necessarily a life-threatening condition. Although there is no definitive treatment, phototherapy should be attempted first. Treatment of primary disease including strict glycaemic control combined with physical therapy should be also employed.",
author = "F. Rongioletti and F. Kaiser and E. Cinotti and D. Metze and M. Battistella and Calzavara-Pinton, {P. G.} and K. Damevska and G. Girolomoni and J. Andr{\'e} and Perrot, {J. L.} and W. Kempf and B. Cavelier-Balloy",
year = "2015",
month = "12",
day = "1",
doi = "10.1111/jdv.13272",
language = "English",
volume = "29",
pages = "2399--2404",
journal = "Journal of the European Academy of Dermatology and Venereology",
issn = "0926-9959",
publisher = "wiley",
number = "12",

}

TY - JOUR

T1 - Scleredema. A multicentre study of characteristics, comorbidities, course and therapy in 44 patients

AU - Rongioletti, F.

AU - Kaiser, F.

AU - Cinotti, E.

AU - Metze, D.

AU - Battistella, M.

AU - Calzavara-Pinton, P. G.

AU - Damevska, K.

AU - Girolomoni, G.

AU - André, J.

AU - Perrot, J. L.

AU - Kempf, W.

AU - Cavelier-Balloy, B.

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Background The prognostic and therapeutic features of scleredema are poorly documented. Objectives To describe the characteristics of patients with scleredema regarding demographics, clinical characteristics, comorbidities, therapeutic interventions and course. Methods We conducted a retrospective multicentre study. Results We identified 44 patients (26 men).The mean age at diagnosis was 53.8 years. The most common associated disorders were endocrine/metabolic diseases including 30 patients suffering from diabetes, mostly type 2 diabetes. Monoclonal gammopathies were confirmed in five cases. A preceding respiratory tract infection was not a feature. Treatments with different combination or sequential modalities were used with variable results. Phototherapy (UVA1 or PUVA) was the treatment associated with higher, although partial response. Systemic corticosteroids and immunosuppressive drugs were reserved to patients with severe disease in whom phototherapy had failed or for patients with multiple myeloma. Forty-one patients were followed up (mean period: 32.2 months).Thirty-nine patients are alive, 30 with and 9 without skin disease. Two patients died of cardiovascular complications due to myeloma and severe diabetes. Conclusions Scleredema is a chronic debilitating disease associated with diabetes and metabolic syndrome, unresponsive to various treatments but not necessarily a life-threatening condition. Although there is no definitive treatment, phototherapy should be attempted first. Treatment of primary disease including strict glycaemic control combined with physical therapy should be also employed.

AB - Background The prognostic and therapeutic features of scleredema are poorly documented. Objectives To describe the characteristics of patients with scleredema regarding demographics, clinical characteristics, comorbidities, therapeutic interventions and course. Methods We conducted a retrospective multicentre study. Results We identified 44 patients (26 men).The mean age at diagnosis was 53.8 years. The most common associated disorders were endocrine/metabolic diseases including 30 patients suffering from diabetes, mostly type 2 diabetes. Monoclonal gammopathies were confirmed in five cases. A preceding respiratory tract infection was not a feature. Treatments with different combination or sequential modalities were used with variable results. Phototherapy (UVA1 or PUVA) was the treatment associated with higher, although partial response. Systemic corticosteroids and immunosuppressive drugs were reserved to patients with severe disease in whom phototherapy had failed or for patients with multiple myeloma. Forty-one patients were followed up (mean period: 32.2 months).Thirty-nine patients are alive, 30 with and 9 without skin disease. Two patients died of cardiovascular complications due to myeloma and severe diabetes. Conclusions Scleredema is a chronic debilitating disease associated with diabetes and metabolic syndrome, unresponsive to various treatments but not necessarily a life-threatening condition. Although there is no definitive treatment, phototherapy should be attempted first. Treatment of primary disease including strict glycaemic control combined with physical therapy should be also employed.

UR - http://www.scopus.com/inward/record.url?scp=84959331815&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959331815&partnerID=8YFLogxK

U2 - 10.1111/jdv.13272

DO - 10.1111/jdv.13272

M3 - Article

VL - 29

SP - 2399

EP - 2404

JO - Journal of the European Academy of Dermatology and Venereology

JF - Journal of the European Academy of Dermatology and Venereology

SN - 0926-9959

IS - 12

ER -